| UniProt ID | CLM7_HUMAN | |
|---|---|---|
| UniProt AC | A8K4G0 | |
| Protein Name | CMRF35-like molecule 7 | |
| Gene Name | CD300LB | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 201 | |
| Subcellular Localization |
Cell membrane Single-pass type I membrane protein. |
|
| Protein Description | Acts as an activating immune receptor through its interaction with ITAM-bearing adapter TYROBP, and also independently by recruitment of GRB2.. | |
| Protein Sequence | MWLPPALLLLSLSGCFSIQGPESVRAPEQGSLTVQCHYKQGWETYIKWWCRGVRWDTCKILIETRGSEQGEKSDRVSIKDNQKDRTFTVTMEGLRRDDADVYWCGIERRGPDLGTQVKVIVDPEGAASTTASSPTNSNMAVFIGSHKRNHYMLLVFVKVPILLILVTAILWLKGSQRVPEEPGEQPIYMNFSEPLTKDMAT | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 86 | Phosphorylation | KDNQKDRTFTVTMEG CCCCCCCEEEEEEEC | 33.52 | 26270265 | |
| 88 | Phosphorylation | NQKDRTFTVTMEGLR CCCCCEEEEEEECCC | 17.91 | 26270265 | |
| 90 | Phosphorylation | KDRTFTVTMEGLRRD CCCEEEEEEECCCCC | 13.37 | 26270265 | |
| 188 | Phosphorylation | EPGEQPIYMNFSEPL CCCCCCCEECCCCCC | 7.84 | 16920917 |
| Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
|---|---|---|---|---|---|---|
| 188 | Y | Phosphorylation | Kinase | FYN | P06241 | Uniprot |
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of CLM7_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of CLM7_HUMAN !! | ||||||
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Phosphorylation | |
| Reference | PubMed |
| "Analysis of mouse LMIR5/CLM-7 as an activating receptor: differentialregulation of LMIR5/CLM-7 in mouse versus human cells."; Yamanishi Y., Kitaura J., Izawa K., Matsuoka T., Oki T., Lu Y.,Shibata F., Yamazaki S., Kumagai H., Nakajima H., Maeda-Yamamoto M.,Tybulewicz V.L.J., Takai T., Kitamura T.; Blood 111:688-698(2008). Cited for: PHOSPHORYLATION AT TYR-188, INTERACTION WITH TYROBP, AND FUNCTION. | |
| "Molecular and functional characterization of CD300b, a new activatingimmunoglobulin receptor able to transduce signals through twodifferent pathways."; Martinez-Barriocanal A., Sayos J.; J. Immunol. 177:2819-2830(2006). Cited for: NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY,PHOSPHORYLATION AT TYR-188, MUTAGENESIS OF LYS-158 AND TYR-188, ANDINTERACTION WITH TYROBP. | |